Breaking News Instant updates and real-time market news.

ABC

AmerisourceBergen

$77.43

-0.8 (-1.02%)

, AMAG

Amag Pharmaceuticals

$10.44

-0.91 (-8.02%)

04:55
05/08/19
05/08
04:55
05/08/19
04:55

Deutsche Bank to hold a conference

44th Annual Healthcare Conference will be held in Boston on May 7-8.

ABC

AmerisourceBergen

$77.43

-0.8 (-1.02%)

AMAG

Amag Pharmaceuticals

$10.44

-0.91 (-8.02%)

AZN

AstraZeneca

$37.96

-0.4 (-1.04%)

ANTM

Anthem

$264.77

-3.99 (-1.48%)

BAYRY

Bayer

$0.00

(0.00%)

BRKS

Brooks Automation

$39.92

0.15 (0.38%)

DCPH

Deciphera

$22.49

-1.25 (-5.27%)

ESPR

Esperion

$48.46

0.17 (0.35%)

FMS

Fresenius Medical

$40.93

-1.105 (-2.63%)

GSK

GlaxoSmithKline

$39.58

-0.4 (-1.00%)

HOLX

Hologic

$45.65

-1.03 (-2.21%)

ICLR

Icon

$137.35

-3.84 (-2.72%)

LMAT

LeMaitre

$27.26

-0.48 (-1.73%)

MGNX

MacroGenics

$17.86

-0.53 (-2.88%)

NOVO

Novo Group Inc

$0.00

(0.00%)

NVCR

Novocure

$47.62

-1.27 (-2.60%)

SN

Sanchez Energy

$0.00

(0.00%)

SYRS

Syros Pharmaceuticals

$6.55

-0.73 (-10.03%)

TECH

Bio-Techne

$201.47

-5.96 (-2.87%)

TLGT

Teligent

$0.92

-0.0676 (-6.84%)

TMO

Thermo Fisher

$271.69

-7.3 (-2.62%)

WAT

Waters

$213.25

-4.575 (-2.10%)

EVTCY

Evotec

$0.00

(0.00%)

  • 08

    May

  • 09

    May

  • 13

    May

  • 14

    May

  • 14

    May

  • 15

    May

  • 16

    May

  • 16

    May

  • 16

    May

  • 18

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 29

    May

  • 29

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 03

    Jun

  • 05

    Jun

  • 06

    Jun

  • 20

    Jun

  • 23

    Jun

  • 13

    Nov

  • 02

    Dec

ABC AmerisourceBergen
$77.43

-0.8 (-1.02%)

04/10/19
04/10/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Reduce from Hold at HSBC with analyst Erwan Rambourg saying the returns from Apple's recent announcements, including the Apple News+ premium news subscription, the Apple Card in partnership with Goldman Sachs (GS), Apple Arcade games as part of the App store and video subscription Apple TV+, could "take some time to extract." 2. AmerisourceBergen (ABC) downgraded to In Line from Outperform at Evercore ISI with analyst Michael Cherry citing group profit questions, lack of clarity with PharMEDium, and a reduction in multiple for peers Cardinal Health (CAH) and McKesson (MCK). 3. Novartis (NVS) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Mark Purcell saying the spinoff of Alcon will put more attention on the generics risk Novartis faces in its pharma business. 4. TerraForm Power (TERP) downgraded to Sell from Neutral at Goldman Sachs with analyst Brian Lee saying that while the company is in the midst of an operational transition that may improve cash flow and dividend flexibility, the upside appears to be priced in. 5. Foot Locker (FL) assumed with a Neutral from Buy at Citi with analyst Paul Lejuez saying while Foot Locker has "tailwinds at its back" in North America with comps inflecting positively in Q4, the company still faces many of the same headwinds as other specialty retailers given its "significant" mall exposure and EBIT pressure from direct-to-consumer. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/11/19
GUGG
04/11/19
INITIATION
GUGG
Buy
AmerisourceBergen initiated with a Buy at Guggenheim
04/10/19
EVER
04/10/19
DOWNGRADE
EVER
In Line
AmerisourceBergen downgraded to In Line from Outperform at Evercore ISI
04/10/19
BOFA
04/10/19
DOWNGRADE
BOFA
Underperform
AmerisourceBergen downgraded to Underperform from Buy at BofA/Merrill
BofA/Merrill analyst Michael Cherry downgraded AmerisourceBergen (ABC) two notches to Underperform from Buy citing group profit questions, lack of clarity with PharMEDium, and a reduction in multiple for peers Cardinal Health (CAH) and McKesson (MCK).
AMAG Amag Pharmaceuticals
$10.44

-0.91 (-8.02%)

03/19/19
RHCO
03/19/19
INITIATION
Target $14
RHCO
Hold
Amag Pharmaceuticals initiated with a Neutral at SunTrust
SunTrust analyst Gregg Gilbert initiated Amag Pharmaceuticals with a Neutral rating and a price target of $14, citing the company's focus to address areas of unmet need, such as "in Women's Healt hand the hospital setting". The analyst believes that the management is "steering the company in the right direction" to diversify its revenue base, but reserves a more constructive rating until more signs of regulatory and commercial execution. Gilbart adds that the "recent news on a negative clinical trial for Makena" is also giving him pause.
03/14/19
CANT
03/14/19
NO CHANGE
Target $14
CANT
Neutral
Amag Pharmaceuticals price target lowered to $14 from $17 at Cantor Fitzgerald
Cantor Fitzgerald analyst Matthew Lillis lowered his price target for Amag Pharmaceuticals to $14 from $17 saying failure of the post-approval Makena trial is a "clear setback for the company." The trial result reinforces the importance of the next 12-18 months for Amag to demonstrate that existing and pipeline assets can adequately replace lost Makena revenue, Lillis tells investors in a research note. He reiterates a Neutral rating on the shares.
03/08/19
PIPR
03/08/19
NO CHANGE
Target $13
PIPR
Neutral
Piper says Makena 'may well be a zero,' cuts Amag target to $13
Piper Jaffray analyst Christopher Raymond lowered his price target for Amag Pharmaceuticals to $13 from $20 and is "incrementally cautious" on the shares after the company announced that Makena's confirmatory study required for full approval failed to meet its co-primary endpoints. With this failure, it's entirely possible that FDA requires the wholesale withdrawal of the entire Makena franchise, Raymond tells investors in a research note titled "Makena May Well Be a Zero After PROLONG Failure." Further, the analyst adds that Amag's annual filing last Friday contained "somewhat concerning disclosures." Among other negative tidbits that included new risk language around continued supply issues as well as autoinjector failures for Makena SubQ, management inserted new, disconcerting risk language about the company's ability to service its debt load, contends Raymond. He keeps a Neutral rating on Amag Pharmaceuticals. The stock in morning trading is down 19%, or $2.57, to $11.16.
02/07/19
PIPR
02/07/19
NO CHANGE
PIPR
Neutral
Piper maintains 'cautious stance' on Amag, still sees meaningful risk
After Amag Pharmaceuticals reported what Piper Jaffray analyst Christopher Raymond called "an in-line Q418 print" and maintained its FY19 guidance, the analyst said he is maintaining his cautious stance and Neutral rating on the stock. Raymond said a sales force restructuring resulting in 110 positions being eliminated, which he views as the right call, was "the only incremental update [he] gleaned from the call." He believes the sales force cuts are "indicative of the challenges facing the women's health franchise" and still sees risk for next quarter's readout of Makena's confirmatory trial, Raymond tells investors in a post-earnings research note.
AZN AstraZeneca
$37.96

-0.4 (-1.04%)

04/29/19
PART
04/29/19
UPGRADE
PART
Hold
AstraZeneca upgraded to Hold from Sell at Pareto
04/02/19
04/02/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) downgraded to Sell from Neutral at UBS with analyst Michael Leuchten saying last week's oncology deal with Japan's Daiichi Sankyo suggests limited cash generation in the near term and is a sign of slow margin recovery. 2. Alcoa (AA) downgraded to Neutral from Outperform at Credit Suisse with analyst Curt Woodworth saying China is set to accelerate supply growth over the next several years as capacity swaps convert to new smelters and provincial focus pivots to growth model. 3. Pacific Biosciences (PACB) downgraded to Equal Weight from Overweight at Stephens with analyst Drew Jones saying the shares are within 10% of the looming purchase price by Illumina (ILMN). 4. Wingstop (WING) downgraded to Neutral from Buy at Guggenheim with analyst Matthew DiFrisco saying he sees increased risk to moderating new store growth and the current valuation multiple. 5. DowDuPont (DWDP) downgraded to Neutral from Buy at Citi and BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/01/19
04/01/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. UPS (UPS) upgraded to Buy from Hold at Berenberg with analyst Joel Spungin saying he is increasingly confident that UPS will deliver margin improvement in both its International business and the U.S. this year, following an in-depth review of European parcel markets. 2. AstraZeneca (AZN) upgraded to Outperform from Market Perform at Cowen with analyst Steve Scala saying the 5% stock decline on news of the company's partnership with Daiichi Sankyo for trastuzumab deruxtecan, which he calls a "promising" breast cancer drug, offers a compelling entry point. 3. Energizer (ENR) upgraded to Conviction Buy from Neutral at Goldman Sachs with analyst Jason English saying he sees a credible path to top-tier EBIT, EBITDA and EPS growth over the next three years "fueled almost entirely" by debt-reduction and synergies from its recently completed deals for the Global Battery & Lighting business and Global Auto Care business of Spectrum Brands (SPB). 4. Anadarko (APC) resumed with a Buy from Neutral at Citi with analyst Robert Morris citing the stock's underperformance over the past three months and the company's recent success in the Delaware Basin for the upgrade. 5. F5 Networks (FFIV) upgraded to Buy from Neutral at Nomura Instinet with analyst Jeffrey Kvaal saying "long an out-of-favor name," F5 shares are now ~25% below their 2018 peak following the acquisition of Nginx. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/02/19
UBSW
04/02/19
DOWNGRADE
UBSW
Sell
AstraZeneca downgraded to Sell from Neutral at UBS
UBS analyst Michael Leuchten downgraded AstraZeneca to Sell from Neutral and lowered his price target for the shares to GBP 54 from GBP 59. Last week's oncology deal with Japan's Daiichi Sankyo suggests limited cash generation in the near term and is a sign of slow margin recovery, Leuchten tells investors in a research note. He believes AstraZeneca can't generate enough cash flow to support its current enterprise value.
ANTM Anthem
$264.77

-3.99 (-1.48%)

04/18/19
LEER
04/18/19
NO CHANGE
LEER
Medicare-For-All risk overblown, investors should buy MCOs, says SVB Leerink
SVB Leerink analyst Ana Gupte believes Medicare-For-All risk is overblown, not the same as 2008/09, and recommends investors step in now to buy MCOs. The analyst believes it is a "once in a decade opportunity" to get high quality names at these depressed multiples, with UnitedHealth (UNH), Anthem (ANTM), and Humana (HUM) being her favorites.
04/23/19
UBSW
04/23/19
INITIATION
Target $294
UBSW
Buy
Anthem initiated with a Buy at UBS
UBS analyst Whit Mayo started Anthem with a Buy rating and $294 price target. The analyst forecasts "industry-leading" 20% earnings growth through 2020. Current share levels price in negative long-term growth, resemble 2012-2013 sector discounts, and offer up a favorable 2.2:1 upside/downside, Mayo tells investors in a research note.
04/26/19
CLVD
04/26/19
NO CHANGE
CLVD
Anthem won Blue Cross of Idaho PBM account, says Cleveland Research
Cleveland Research said it believes that Anthem's (ANTM) Ingenio recently won the PBM contract for Blue Cross of Idaho away from CVS Health (CVS), the firm told investors in a research note.
04/25/19
RHCO
04/25/19
NO CHANGE
Target $300
RHCO
Hold
Anthem price target lowered to $300 from $340 at SunTrust
SunTrust analyst David MacDonald lowered his price target on Anthem to $300 to reflect market multiples and also kept his Hold rating after the company's Q1 results. The analyst notes however that the quarter was "marked by enrollment growth across products" along with solid cash flow and a raise in FY19 outlook. MacDonald adds that he remains upbeat on Anthem's government segment.
BAYRY Bayer
$0.00

(0.00%)

03/21/19
03/21/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Biogen (BIIB) downgraded to Market Perform from Outperform at Wells Fargo after the company reported the failure of two phase 3 trials for a potential treatment of Alzheimer's disease. 2. Magna (MGA) downgraded to Market Perform from Outperform at BMO Capital with analyst Peter Sklar noting BMW's (BMWYY) lowered 2019 earnings guidance on numerous headwinds reflects how difficult it is for auto manufacturers to grow earnings during a period of flat to declining vehicle production volumes. 3. Munich Re (MURGY) downgraded to Hold from Buy at Jefferies with analyst Philip Kett saying he believes the recent rally leaves less room for valuation upside. 4. Nufarm (NFRMY) downgraded to Neutral from Overweight at JPMorgan with analyst Donald Carducci noting glyphosate is becoming a concern for Bayer (BAYRY) due to a recent U.S. case progressing to phase two. 5. Micron (MU) downgraded to Sell from Neutral at Citi with analyst Christopher Danely saying Micronis trying its best but "you can't swim against a tsunami". This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/20/19
SBSH
03/20/19
NO CHANGE
SBSH
Bayer shares likely to remain 'depressed' pending trial success, says Citi
While sentiment will "clearly take a knock" at the second Roundup trial going against Bayer (BAYRY), both verdicts were delivered by juries in California and EUR 22B of litigation risk is already priced into the shares, Citi analyst Peter Verdult tells investors in a research note. The analyst says his legal checks continue to instruct him to be more focused on the upcoming Hall vs. Monsanto trial being held in St Louis from April 1. He says that verdict will better determine whether his estimate of a potential settlement liability of $1B-$6B needs to be refined. However, Bayer shares will "likely remain depressed" until there is evidence of the company prevailing in one or more of the six cases to go to trial in 2019, Verdult contends. He keeps a Buy rating on the stock but prefers other Pharma plays AstraZeneca (AZN), Sanofi (SNY), Novartis (NVS) and Merck (MRK).
03/31/19
DBAB
03/31/19
DOWNGRADE
DBAB
Hold
Bayer downgraded to Hold from Buy at Deutsche Bank
04/01/19
BREN
04/01/19
DOWNGRADE
BREN
Hold
Bayer resumed with a Hold from Buy at Berenberg
Berenberg transferred coverage of Bayer to analyst Sebastian Bray and downgraded the stock to Hold from an under review designation. The analyst sees downside from legal settlements following the unfavorable glyphosate verdicts. He has a price target of EUR 67 for the shares.
BRKS Brooks Automation
$39.92

0.15 (0.38%)

12/17/18
SBSH
12/17/18
NO CHANGE
SBSH
Buy
Citi adds 'positive catalyst watch' on Brooks Automation
Citi analyst Amanda Scarnati adds a "positive catalyst watch" on Brooks Automation after meeting with the company's management. The analyst says Brooks sounded the most positive of the group on her firm's bus tour, largely due to its "solid exposure to the life sciences market," Scarnati tells investors in a research note. The analyst expects Brooks Automation's relative share outperformance to continue in the first half of 2019 as the life sciences business continues to grow as a percentage of sales and the sale of the "low growth" semi cryo business closes. Scarnati has a Buy rating on the shares.
09/04/18
RILY
09/04/18
NO CHANGE
Target $50
RILY
Buy
Brooks Automation price target raised to $50 from $40 at B. Riley FBR
B. Riley FBR analyst Craig Ellis raised his price target for Brooks Automation to $50 citing the company's intensifying push into life sciences. The analyst reiterates a Buy rating on the shares.
01/23/19
SBSH
01/23/19
NO CHANGE
SBSH
Citi moves Lam Research to top pick in Semiconductor Capital Equipment
Citi analyst Atif Malik lowered his 2019 wafer-fab equipment spend estimate to $40B, or down 22% year-over-year, versus his prior $44B to reflect weak Korea memory spending. The analyst also moved Lam Research (LRCX) to his number one pick and Applied Materials (AMAT) to number two. Previous top pick KLA-Tencor (KLAC) moves down to number three to reflect "prior stock performance into and out of memory downturns." Among smaller caps, the analyst moves Brooks Automation (BRKS) up to his top pick "due to the strength of the life sciences portfolio which should bring stability to top line relative to semi peers." Malik thinks Semiconductor Capital Equipment group returns look attractive "with the rationale to buy and hold long-term."
11/20/18
FBCO
11/20/18
NO CHANGE
Target $26
FBCO
Neutral
Brooks Automation price target lowered to $26 from $32 at Credit Suisse
Credit Suisse analyst John Pitzer lowered his price target for Brooks Automation to $26 from $32 after the company reported Q3 revenues in line, with EPS slightly above estimates, and guided Q4 below due to the divestiture of the Semiconductor Cryogenics business and the acquisition of the Genewiz business. The analyst reiterates a Neutral rating on the shares.
DCPH Deciphera
$22.49

-1.25 (-5.27%)

03/06/19
PIPR
03/06/19
NO CHANGE
PIPR
Departure of Gottlieb brings some biopharma uncertainty, says Piper Jaffray
Piper Jaffray remains "largely bullish" on the biopharma sector but acknowledges a "new and unexpected" source of uncertainty now with the announced departure of FDA commissioner Scott Gottlieb, analysts led by Christopher Raymond tell investors in a research note. With a track record of favoring innovation and pushing for increased regulatory efficiency while also advocating for more competition, Dr. Gottlieb was about as "market friendly, patient focused and industry friendly as one could have hoped," Piper writes. The firm adds that while it has no reason to believe the next commissioner "will be quite as radical and potentially damaging to the industry," it does think investors would do well to watch the selection process very closely.
03/14/19
PIPR
03/14/19
NO CHANGE
Target $50
PIPR
Overweight
Deciphera development of ripretinib 'progressing nicely', says Piper Jaffray
Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $50 price target on Deciphera after its in-line Q4 results, saying the company's development of ripretinib is progressing nicely with ongoing phase 3 enrollment in INTRIGUE study and results for INVICTUS study expected later this year. The analyst remains positive on the shares given the company's "catalyst-rich" second half of the year on tap.
03/12/19
PIPR
03/12/19
NO CHANGE
PIPR
Biopharma stocks should be up sharply on Sharpless selection, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said he expects biopharma stocks to be up sharply on news that former National Cancer Institute director Ned Sharpless will be named acting FDA commissioner. The biotech sector "experienced a swoon of sorts" since Scott Gottlieb announced his departure, but with the announcement of Gottlieb's favored choice as successor Raymond believes the FDA will remain "on its current industry-friendly and efficiency driven trajectory," the analyst tells investors.
01/03/19
PIPR
01/03/19
NO CHANGE
PIPR
Piper sees Alexion, Biogen as potential targets after Celgene buyout
Piper Jaffray analyst Christopher Raymond remains "bullish on biotech" in the wake the announced acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) for $74B in cash and stock, representing a 54% premium from yesterday's close. In a research note titled "Bristol for CELG - In Retrospect, it Makes Perfect Sense," Raymond says the market is likely to ask "who's next?" Among large-caps, Alexion Pharmaceuticals (ALXN) and Biogen (BIIB) would seem to make sense as potential targets, as well as BioMarin (BMRN), Raymond writes. And while any smid cap could likely be seen as a take-out candidate, Aimmune Therapeutics (AIMT), Deciphera Pharmaceuticals (DCPH) and Rigel Pharmaceuticals (RIGL) "in particular could make sense to any strategic buyer," adds the analyst.
ESPR Esperion
$48.46

0.17 (0.35%)

05/06/19
FBCO
05/06/19
NO CHANGE
Target $90
FBCO
Outperform
Esperion price target raised to $90 from $79 at Credit Suisse
Credit Suisse analyst Martin Auster raised his price target for Esperion to $90 from $79 as he believes the FDA's decision to accept the BA NDA and not hold an AdCom will be viewed favorably and likely will result in substantial upside as investors price in a higher assumed regulatory PoS. While the FDA could request an AdCom at a later date, the analyst is not aware of an example where an AdCom was requested after a sponsor was told it was not needed at acceptance. Auster reiterates an Outperform rating on the shares.
05/06/19
BOFA
05/06/19
UPGRADE
BOFA
Neutral
Esperion upgraded to Neutral from Underperform at BofA/Merrill
05/06/19
JEFF
05/06/19
NO CHANGE
Target $85
JEFF
Buy
No plans for FDA panel removes Esperion bear case, says Jefferies
Jefferies analyst Michael Yee believes the FDA's communication to Esperion Therapeutic that it does not plan to host an advisory panel removes a bear argument. The analyst is surprised by the news and keeps a Buy rating on the shares with an $85 price target.
05/02/19
SBSH
05/02/19
NO CHANGE
Target $23
SBSH
Buy
Amarin selloff creates attractive entry point, says Citi
Citi analyst Joel Beatty believes the selloff yesterday in shares of Amarin (AMRN) brings an attractive entry point. He raised his price target for the stock to $23 from $20 and keeps a Buy rating on the name. The analyst sees five potential upside catalysts this year, including a likely supportive ICER cost-effectiveness review and potential priority review from the FDA. Further, while an acquisition of Amarin is possible, the company acquiring The Medicines Co. (MDCO) or Esperion (ESPR) "could also be a viable path," says Beatty.
FMS Fresenius Medical
$40.93

-1.105 (-2.63%)

10/26/18
UBSW
10/26/18
UPGRADE
UBSW
Buy
Fresenius Medical upgraded to Buy from Neutral at UBS
10/26/18
UBSW
10/26/18
UPGRADE
UBSW
Buy
Fresenius Medical upgraded to Buy from Neutral at UBS
UBS analyst Ian Douglas-Pennant upgraded Fresenius Medical to Buy while lowering his price target for the shares to EUR 82 from EUR 86. The analyst says the Q3 pre-release selloff presents a buying opportunity.
11/20/18
RHCO
11/20/18
NO CHANGE
Target $46
RHCO
Buy
Fresenius Medical price target lowered to $46 from $62 at SunTrust
SunTrust analyst David MacDonald lowered his price target on Fresenius Medical to $46 to reflect its "soft" Q3 results with a lower implied valuation of 10-times forward EBITDA. The analyst believes that given the mixed fundamentals, the stock is a "show me" story, even though he keeps his Buy rating on Fresenius Medical longer term based on its "solid core volume trends, attractive overarching industry drivers, a diversified business model, and strong free cash generation".
02/21/19
RHCO
02/21/19
NO CHANGE
Target $48
RHCO
Buy
Fresenius Medical price target raised to $48 from $40 at SunTrust
SunTrust analyst David MacDonald raised his price target on Fresenius Medical to $48 and kept his Buy rating after its Q4 results yesterday, saying the quarter was "marked by solid organic trends, ongoing efficiency gains and strong cash flow." The analyst anticipates the company's 2019 to be a year of investment but sees the incremental spending driving more optimization and positioning Fresenius Medical for "attractive growth opportunities". MacDonald adds that he is positive on the company's pending acquisition of NxStage Medical (NXTM) given the market shift "towards the home".
GSK GlaxoSmithKline
$39.58

-0.4 (-1.00%)

01/31/19
ARGS
01/31/19
UPGRADE
Target $55
ARGS
Pfizer upgraded to Buy from Hold at Argus
Argus analyst David Toung upgraded Pfizer (PFE) to Buy with a price target of $55, saying he anticipates an upward revenue inflection point in 2021 after flat sales in the second half of 2019 and first half of 2020. After cycling through Lyrica loss of exclusivity over the next year, the analyst anticipates Pfizer to benefit from optimized portfolio of assets as it completes its consumer healthcare business joint venture with GlaxoSmithKline (GSK). Toung adds that while he does not "expect major transformational deals", he does see the management pursuing "acquisitions and divestitures that improve long-term profitability".
02/01/19
WELS
02/01/19
NO CHANGE
Target $46
WELS
Market Perform
Perrigo's ProAir opportunity 'may be vaporizing,' says Wells Fargo
Wells Fargo analyst David Maris noted that GlaxoSmithKline (GSK) launched an authorized generic of Ventolin on January 15 and he has now learned that Teva (TEVA) may have "surprisingly launched" an authorized generic of ProAir in response to the generic Ventolin pressure prior to Perrigo's (PRGO) approval. Pricing pressure from generic Ventolin, in addition to the launch of an authorized generic well ahead of Perrigo's own generic ProAir launch, seem to have significantly diminished Perrigo's generic ProAir opportunity, Maris tells investors. He keeps a Market Perform rating and $46 price target on Perrigo shares.
01/31/19
WELS
01/31/19
NO CHANGE
WELS
Outperform
FDA approval of Mylan's Advair 'overdue,' says Wells Fargo
Wells Fargo analyst David Maris believes that while "overdue," FDA's approval of Mylan's (MYL) generic Advair is good news. Many investors were expecting this to be further delayed, he notes, adding that he currently has $50M generic Advair in his model for Q1. The analyst believes GlaxoSmithKline (GSK) will launch an authorized generic, and with Advair's already declining revenue, the generic Advair opportunity may turn out to be a great-to-have since it shows Mylan's ability to get complex generics approved, but may not be a game changer. Maris reiterates an Outperform rating on Mylan's shares.
02/22/19
UBSW
02/22/19
DOWNGRADE
UBSW
Neutral
GlaxoSmithKline downgraded to Neutral from Buy at UBS
UBS analyst Laura Sutcliffe downgraded GlaxoSmithKline to Neutral and lowered her price target for the shares to 1,650p from 1,700p. Concerns around the company's HIV franchise are likely to keep a lid on the shares, Sutcliffe tells investors in a research note. Further, she believes consensus estimates for 2019 are "slightly too high."
HOLX Hologic
$45.65

-1.03 (-2.21%)

01/04/19
COWN
01/04/19
DOWNGRADE
COWN
Market Perform
Hologic downgraded to Market Perform from Outperform at Cowen
01/02/19
01/02/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Henry Schein (HSIC) downgraded to Neutral from Outperform at Baird with analyst Jeff Johnson saying he is more cautious on the combination of the dental sector's secular overhangs, softer Q4 patient volume checks, and accelerating equipment pricing pressures. 2. Conagra Brands (CAG) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Jason English saying while the stock's 41% decline since October 23 is overdone, the "path of recovery is likely to be protracted." 3. BioMarin (BMRN) downgraded to Market Perform from Outperform at Raymond James with analyst Laura Chico saying BioMarin lacks near-term catalysts which makes it more vulnerable in a "risk off" environment. 4. Hologic (HOLX) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst David Lewis saying his checks with about 40 medspas highlighted market saturation of body sculpting devices. 5. Louisiana-Pacific (LPX) downgraded to Neutral from Buy at BofA/Merrill with analyst George Staphos citing the steep drop-off in 2H 2018 panel pricing and challenging 1H 2019 comparisons versus 1H 2018. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/31/19
PIPR
01/31/19
NO CHANGE
Target $49
PIPR
Overweight
Hologic price target raised to $49 from $45 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for Hologic to $49 after the company reported fiscal Q1 results in-line with its preannouncement and raised guidance for fiscal 2019. The analyst continues to believe "core Hologic is moving in the right direction" and and he keeps an Overweight rating on the shares. He views the quarter as positive for the company and believes the guidance is reasonable.
04/24/19
PIPR
04/24/19
NO CHANGE
Target $49
PIPR
Overweight
Hologic checks suggest worsening Cynosure trends, says Piper Jaffray
Piper Jaffray analyst William Quirk says his eBay (EBAY) channel checks suggest Hologic's (HOLX) positive trends in his earlier research have reversed with more used Cynosure lasers hitting third party websites and prices trending down. While Cynosure represents just ~10% of Hologic's total revenue, it carries a "heavy psychological burden on the share price," Quirk tells investors in a research note. He maintains an Overweight rating on Hologic with a $49 price target, but recognizes the company's March quarter results may bring a better entry point if his checks prove accurate.
ICLR Icon
$137.35

-3.84 (-2.72%)

04/02/19
WOLF
04/02/19
INITIATION
Target $149
WOLF
Outperform
Icon initiated with an Outperform at Wolfe Research
Wolfe Research initiated Icon with an Outperform and $149 price target to reflect leverage growth and share underperformance.
02/25/19
RHCO
02/25/19
NO CHANGE
Target $161
RHCO
Buy
Icon price target raised to $161 from $150 at SunTrust
SunTrust analyst Sandy Draper raised his price target on Icon to $161 and kept his Buy rating after its Q4 earnings beat, maintained 2019 guidance, and strong book-to-bill. The analyst believes that the consensus for the company's earnings can move higher through the year end, driven by Icon's rising operating leverage from flat SG&A expenses and stock buybacks.
01/11/19
GSCO
01/11/19
UPGRADE
Target $151
GSCO
Conviction Buy
Iqvia upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Robert Jones added Iqvia Holdings (IQ) to his firm's Americas Conviction List while keeping a Buy rating on the shares. The analyst lowered his price target for the shares to $151 from $152. He sees "several drivers of upside" in 2019 against a "very healthy" industry backdrop. Iqvia's backlog growth along with an industry leading book-to-bill indicate its offering is resonating in the market, Jones tells investors in a research note. He believes the company's upcoming commentary accompanying 2019 guidance could serve as a potential catalyst for the shares. Jones is also positive on shares of Icon (ICLR).
01/25/19
MZHO
01/25/19
UPGRADE
Target $150
MZHO
Buy
Icon upgraded to Buy from Neutral at Mizuho
Mizuho analyst Ann Hynes upgraded Icon to Buy and raised her price target for the shares to $150 from $146. The recent volatility in the Contract Research Organization group provides a "nice entry point" into Icon shares, Hynes tells investors in a research note. She prefers Icon to the other CROs due to the "quality" of its earnings, "strong" cash conversion, and potential for earnings upside versus its peers.
LMAT LeMaitre
$27.26

-0.48 (-1.73%)

01/23/19
LSCM
01/23/19
NO CHANGE
Target $24
LSCM
Hold
LeMaitre price target lowered to $24 from $30 at Lake Street
Lake Street analyst Brooks O'Neil lowered his price target for LeMaitre Vascular to $24 and maintains a Hold rating on the shares. Toward the end of 2018, LeMaitre backed away from its long-term guidance for 10% revenue growth and 20% earnings growth, O'Neil tells investors in a research note.
10/08/18
BRRR
10/08/18
UPGRADE
Target $34
BRRR
Outperform
LeMaitre upgraded to Outperform from Market Perform at Barrington
Barrington analyst Michael Petusky upgraded LeMaitre Vascular to Outperform with a $34 price target. Friday's 21% on the disappointing preliminary Q3 results was overdone and provides investors with an attractive entry point, Petusky tells investors in a research note. He believes the shares are "no longer priced for perfection."
10/08/18
10/08/18
UPGRADE
Target $34

Buy
LeMaitre upgraded to Buy post Q3 speed bump at Roth Capital
As previously reported, Roth Capital analyst David Solomon upgraded LeMaitre to Buy from Neutral, while lowering his price target on the shares to $34 from $39. The analyst notes that the company reported in-line Q3 EPS despite a $1.8M revenue shortfall and took down 2018 guidance. While Solomon acknowledged that the company is facing multiple near-term headwinds that motivated both a revision in 2018 guidance and a tabling of its "10 and 20" mantra, he expects winds to reverse by mid-19.
02/20/19
LSCM
02/20/19
NO CHANGE
Target $27
LSCM
Hold
LeMaitre price target raised to $27 from $24 at Lake Street
Lake Street analyst Brooks O'Neil raised his price target for LeMaitre Vascular to $27 saying the company reported "solid" Q4 results as RestoreFlow and Valvulotomes recovered from Q3. However, management does not appear ready to suggest 10% sales and 20% earnings growth "are again in focus," O'Neil tells investors in a post-earnings research note. He keeps a Hold rating on LeMaitre.
MGNX MacroGenics
$17.86

-0.53 (-2.88%)

04/17/19
FBCO
04/17/19
INITIATION
Target $29
FBCO
Outperform
MacroGenics initiated with an Outperform at Credit Suisse
Credit Suisse analyst Michael Morabito started coverage of MacroGenics with an Outperform rating and a $29 price target. The analyst believes MacroGenics is an opportunity driven by a pipeline with multiple upcoming proof-of-concept data readouts. Clinical updates on lead asset margetuximab in breast cancer are likely to drive the stock in the short term, but the base platform holds the most potential value, he contends.
05/03/19
WEDB
05/03/19
UPGRADE
Target $26
WEDB
Outperform
MacroGenics upgraded to Outperform from Neutral at Wedbush
Wedbush analyst David Nierengarten upgraded MacroGenics to Outperform from Neutral and maintained his $26 price target, saying he believes current share price levels provide upside, given potential positive catalysts ahead with updated SOPHIA data at ASCO, and the possibility of a partnership agreement for margetuximab. MacroGenics remains on track to file a BLA in the second half of the year for margetuximab in treating HER2+ metastatic breast cancer, but Nierengarten says he does not expect to see overall survival data until 2020, and when available, will trigger discussions with EU regulators.
05/03/19
WEDB
05/03/19
UPGRADE
WEDB
Outperform
MacroGenics upgraded to Outperform from Neutral at Wedbush
04/12/19
GUGG
04/12/19
INITIATION
GUGG
Neutral
MacroGenics initiated with a Neutral at Guggenheim
Guggenheim analyst Michael Schmidt started MacroGenics with a Neutral rating. The analyst has "lower conviction" in the upside opportunity for the company's assets in the "competitive categories" of breast cancer and acute myeloid leukemia.
NOVO Novo Group Inc
$0.00

(0.00%)

NVCR Novocure
$47.62

-1.27 (-2.60%)

03/19/19
RHCO
03/19/19
INITIATION
Target $50
RHCO
Hold
Novocure initiated with a Hold at SunTrust
SunTrust analyst Gregg Gilbert started Novocure with a Hold rating and $50 price target. The analyst believes the shares now reflect investor optimism for continued growth of Optune in glioblastoma, Medicare coverage for Optune, a mesothelioma approval, and the potential for Optune to have utility in larger indications. While Gilbert does not see enough near-term upside for a Buy rating, he believes Novocure has the potential for "significant" upside over the next few years.
11/02/18
WELS
11/02/18
DOWNGRADE
Target $36
WELS
Market Perform
Novocure downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Larry Biegelsen downgraded Novocure to Market Perform and lowered his price target for the shares to $36 from $41. The analyst cites another quarter of flattish U.S. prescription trends for the downgrade and sees a lack of major catalysts heading into 2019. While year-over-year Optune growth has been solid, there has been little sequential volume growth in the U.S. during 2018 despite positive data and treatment guideline upgrade in the past 12 months, Biegelsen tells investors in a research note. And he sees no clear catalyst in 2019 that would meaningfully accelerate its penetration rate.
10/26/18
MZHO
10/26/18
NO CHANGE
Target $51
MZHO
Buy
Novocure post-earnings selloff 'way overdone,' says Mizuho
Mizuho analyst Difei Yang views yesterday's post-earnings selloff in shares of Novocure as "way overdone." The company's Q3 results were in-line with expectations and the investor reaction was overly focused on negative quarter-over-quarter U.S. prescription growth, Yang tells investors in a research note. The analyst points out that active patients on Optune continued to grow during the quarter, although at a smaller pace in the U.S. She lowered her price target for the shares to $51 from $58 and reiterates a Buy rating on Novocure.
09/25/18
MZHO
09/25/18
NO CHANGE
Target $58
MZHO
Buy
Novocure shares attractive at current levels, says Mizuho
Mizuho analyst Difei Yang reiterates a Buy rating on Novocure with a $58 price target after hosting meetings with management. The analyst believes "significant growth" remains for NovoCure over time as the Optune technology is applied in multiple solid cancer indications. The shares are attractive at current levels relative to the company's growth opportunity, Yang tells investors in a research note.
SN Sanchez Energy
$0.00

(0.00%)

05/08/18
JRCO
05/08/18
DOWNGRADE
JRCO
Accumulate
Sanchez Energy downgraded to Accumulate from Buy at Johnson Rice
08/08/18
RBCM
08/08/18
DOWNGRADE
Target $3.5
RBCM
Sector Perform
Sanchez Energy downgraded to Sector Perform RBC Capital after 'painful' Q2
As report earlier, RBC Capital analyst Brad Heffern downgraded Sanchez Energy to Sector Perform from Outperform and lowered his price target to $3.50 from $6.00. The analyst cites a "painful" Q2 result in a "series of operational missteps", adding that investors are unlikely to give the company much credit from hiring a consultant until they can see some stabilization of its asset base and several quarters of consistent performance.
08/08/18
RBCM
08/08/18
DOWNGRADE
RBCM
Sector Perform
Sanchez Energy downgraded to Sector Perform from Outperform at RBC Capital
SYRS Syros Pharmaceuticals
$6.55

-0.73 (-10.03%)

02/14/19
OPCO
02/14/19
INITIATION
Target $13
OPCO
Outperform
Syros Pharmaceuticals assumed with an Outperform at Oppenheimer
Oppenheimer analyst Mark Breidenbach assumed coverage of Syros Pharmaceuticals with an Outperform rating and a $13 price target. The analyst believes the company's lead program, SY-1425, has demonstrated compelling clinical proof-of-concept in a biomarker-defined population of acute myeloid leukemia patients and has an opportunity for approval in multiple therapeutic settings. However, recent changes in the AML competitive landscape, such as the approval of venetoclax, could limit uptake and prolong development timelines relative to previous estimates, he contends. Nonetheless, Breidenbach sees SY-1425 + azacitidine as a promising combination therapy in AML and expects the company to announce updated development plans in early 2019.
03/08/19
03/08/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tilray (TLRY) initiated with an Underperform at Jefferies. 2. BB&T (BBT) initiated with a Buy at Odeon Capital. 3. Syros Pharmaceuticals (SYRS) initiated with an Outperform at JMP Securities. 4. W&T Offshore (WTI) initiated with a Buy at Stifel. 5. Ichor Holdings (ICHR) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/10/19
PIPR
04/10/19
NO CHANGE
Target $24
PIPR
Overweight
Syros Pharmaceuticals price target lowered to $24 from $28 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for Syros Pharmaceuticals to $24 from $28 to account for dilution of the company's recent $70M capital raise. The analyst, however, reiterates an Overweight rating on the name. Syros is developing potentially best-in-class CDK7 inhibitors, Tenthoff tells investors in a research note. He points out that data from the expansion cohorts in ovarian cancer are expected in Q4.
03/08/19
JMPS
03/08/19
INITIATION
Target $18
JMPS
Outperform
Syros Pharmaceuticals initiated with an Outperform at JMP Securities
JMP Securities transferred coverage of Syros Pharmaceuticals to analyst Jason Butler, who established an Outperform rating and $18 price target on the stock. He believes the company's recently updated clinical development strategies can provide faster paths to market and maximize commercial potential for SY-1425 and SY-1365, Butler tells investors.
TECH Bio-Techne
$201.47

-5.96 (-2.87%)

01/14/19
01/14/19
UPGRADE
Target $180

Overweight
Bio-Techne upgraded to Overweight on favorable backdrop at Stephens
As previously reported, Stephens analyst Drew Jones upgraded Bio-Techne to Overweight from Equal Weight, citing his view of the favorable backdrop for legacy reagents and its sustainable momentum with its protein platforms. The demand for GMP-grade products continues to increase amid an increasing focus on cell therapies and biologics, which Jones said is a great opportunity for Bio-Techne given he views it as well-positioned to gain market share from smaller players who will be unable to make the investments needed to provide high-quality, validated proteins and antibodies. Jones maintains a $180 price target on Bio-Techne shares.
02/06/19
CHLM
02/06/19
NO CHANGE
Target $179
CHLM
Hold
Bio-Techne price target raised to $179 from $154 at Craig-Hallum
Craig-Hallum analyst Alexander Nowak raised his price target for Bio-Techne to $179 from $154 after a strong quarter from its Protein Sciences business and better cost control. The analyst reiterates a Hold rating on the shares.
03/04/19
ARGS
03/04/19
NO CHANGE
Target $230
ARGS
Bio-Techne on track for continued solid revenue growth, says Argus
Argus analyst David Toung believes Bio-Techne remains on-track for continued solid revenue growth driven by strong domestic and international demand for its products. He lowered his estimates to reflect earnings dilution from its recent acquisition, but noted the company is targeting $1B in revenues by 2022. Toung reiterated his Buy rating and $230 price target on Bio-Techne shares.
01/14/19
SPHN
01/14/19
UPGRADE
SPHN
Overweight
Bio-Techne upgraded to Overweight from Equal Weight at Stephens
TLGT Teligent
$0.92

-0.0676 (-6.84%)

03/19/19
RAJA
03/19/19
DOWNGRADE
RAJA
Outperform
Teligent downgraded to Outperform from Strong Buy at Raymond James
03/19/19
03/19/19
DOWNGRADE
Target $2.25

Outperform
Teligent downgraded to Outperform at Raymond James
As previously reported, Raymond James downgraded Teligent to Outperform from Strong Buy and cut its price target to $2.25 from $4. Analyst Eliot Wilbur is taking a more conservative to growth estimates saying the company's injectables strategy has limited visibility through early 2020.
TMO Thermo Fisher
$271.69

-7.3 (-2.62%)

03/25/19
DBAB
03/25/19
NO CHANGE
Target $300
DBAB
Buy
Thermo Fisher price target raised to $300 from $275 at Deutsche Bank
Deutsche Bank analyst Dan Leonard raised his price target for Thermo Fisher to $300 from $275 saying the acquisition of Brammer Bio fills the gap in its contract services offering. The analyst believes Thermo Fisher can continue to exceed market growth rates "despite uniquely challenging comps." He says the acquisition supports his thesis and keeps a Buy rating on the shares.
03/26/19
BTIG
03/26/19
NO CHANGE
Target $310
BTIG
Buy
Thermo Fisher price target raised to $310 from $290 at BTIG
BTIG analyst Sung Ji Nam raised his price target on Thermo Fisher to $310 and kept his Buy rating after its announced $1.7B deal to buy Brammer Bio. The analyst sees "minimal" revenue and earnings impact from the purchase in the near term but sees the company "gaining valuable capabilities to support one of the fastest growing areas within the biopharma end market" as a result of the transaction. Sung Ji Nam concludes that the acquisition makes "financial sense" given Thermo Fisher's "successful foray" into the contract development and manufacturing organization, or CDMO, market.
03/26/19
BARD
03/26/19
NO CHANGE
Target $288
BARD
Outperform
Thermo Fisher price target raised to $288 from $270 at Baird
Baird analyst Catherine Ramsey Schulte reiterated an Outperform rating on Thermo Fisher and raised her price target to $288 from $270 following the company's announcement that it will buy Brammer Bio for $1.7B. In a research note to investors, the analyst says she continues to recommend Thermo Fisher as a core holding, and sees room for organic outperformance throughout 2019 as well as the potential for additional M&A.
04/22/19
NEED
04/22/19
NO CHANGE
Target $312
NEED
Strong Buy
Thermo Fisher price target raised to $312 from $271 at Needham
Needham analyst Stephen Unger raised his price target on Thermo Fisher to $312 and kept his Strong Buy rating ahead of its Q1 results this Wednesday. The analyst sees "solid potential" for an earnings beat on "better-than-expected organic revenue growth in all four segments", also noting that he has a "more bullish view" on the company's prospects for 2019. Unger adds that he is positive on the impact of the "strategic" Brammer Bio acquisition announced by Thermo Fisher last month.
WAT Waters
$213.25

-4.575 (-2.10%)

01/24/19
BARD
01/24/19
DOWNGRADE
Target $211
BARD
Neutral
Baird downgrades Waters to Neutral, says organic growth looks priced in
As reported previously, Baird analyst Catherine Ramsey Schulte downgraded Waters to Neutral from Outperform. The analyst noted its strong Q4 results and positive commentary, but she thinks it will likely take time for new product introductions to improve its competitive positioning and the current valuation already prices in expectations for improved organic growth in 2019. Schulte raised her price target to $211 from $191 on Waters shares.
01/03/19
01/03/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Apple (AAPL) upgraded to Neutral from Reduce at New Street with analyst Pierre Ferragu saying the news is as bad as can be and the thesis is "fully played out." 2. Alphabet (GOOG, GOOGL) upgraded to Buy from Hold at Canaccord with analyst Michael Graham saying revenue growth should continue in the 15-20% range for 2-3 years which coupled with abating margin pressure and share buybacks, should lead to over 15% earnings growth between 2020-2022. 3. First Solar (FSLR) upgraded to Buy from Neutral at Goldman Sachs with analyst Brian Lee saying solar stocks underperformed in 2018 as tariffs, China policy and oversupply drove a cyclical correction. 4. Stryker (SYK) upgraded to Outperform at Evercore ISI with analyst Ross Muken saying 2019 guidance has been de-risked following management commentary and said recent macro survey work suggests 7% organic growth is achievable. 5. Waters (WAT) upgraded to Neutral from Underperform at BofA/Merrill with analyst Derik de Bruin citing an aggressive share buyback program that offers earnings support. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/24/19
BARD
01/24/19
DOWNGRADE
BARD
Neutral
Waters downgraded to Neutral from Outperform at Baird
01/24/19
BTIG
01/24/19
NO CHANGE
Target $260
BTIG
Buy
Waters price target raised to $260 from $212 at BTIG
BTIG analyst Sung Ji Nam raised the price target on Waters Corp to $260 and kept its Buy rating after the company beat on Q4 results and guided FY19 EPS midpoint above consensus. The analyst points to the company's encouraging "solid growth momentum", continued strong demand in China, as well as improving conditions in North America and for the biopharma end market globally. Sung Ji Nam further states that Waters' 2019 outlook suggests that the company's "significant capital deployment capacity" benefited from the 2017 U.S. tax reform.
EVTCY Evotec
$0.00

(0.00%)

04/10/19
DBAB
04/10/19
DOWNGRADE
DBAB
Hold
Evotec downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank downgraded Evotec to Hold from Buy citing valuation.

TODAY'S FREE FLY STORIES

TEVA

Teva

$10.86

-0.18 (-1.63%)

12:11
05/26/19
05/26
12:11
05/26/19
12:11
Hot Stocks
Teva reaches $85M agreement with State of Oklahoma »

Teva Pharmaceuticals USA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESLT

Elbit Systems

$141.85

1.33 (0.95%)

12:08
05/26/19
05/26
12:08
05/26/19
12:08
Hot Stocks
Elbit Systems awarded $127M contract to provide tactical radio system »

Elbit Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

ADM

Archer Daniels

$39.17

-0.03 (-0.08%)

12:05
05/26/19
05/26
12:05
05/26/19
12:05
Hot Stocks
Archer Daniels expands recall of Baker's Corner All Purpose Flour 5lb bags »

ADM Milling is recalling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

JCP

J.C. Penney

$0.93

0.022 (2.42%)

, DDS

Dillard's

$56.57

0.25 (0.44%)

13:29
05/25/19
05/25
13:29
05/25/19
13:29
Periodicals
Target stock triumphs in brutal week for retail, Barron's says »

Earnings season has been…

JCP

J.C. Penney

$0.93

0.022 (2.42%)

DDS

Dillard's

$56.57

0.25 (0.44%)

KSS

Kohl's

$51.11

-0.04 (-0.08%)

JWN

Nordstrom

$33.50

-0.31 (-0.92%)

M

Macy's

$21.00

-0.27 (-1.27%)

TGT

Target

$81.57

2.17 (2.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

JPM

JPMorgan

$109.78

1.14 (1.05%)

, AKZOY

AkzoNobel

$0.00

(0.00%)

13:24
05/25/19
05/25
13:24
05/25/19
13:24
Periodicals
Microsoft, JPMorgan among dividend champions, Barron's says »

Among the companies that…

JPM

JPMorgan

$109.78

1.14 (1.05%)

AKZOY

AkzoNobel

$0.00

(0.00%)

XOM

Exxon Mobil

$74.12

0.33 (0.45%)

MSFT

Microsoft

$126.23

0.04 (0.03%)

CMWAY

Commonwealth Bank of Australia

$0.00

(0.00%)

SIEGY

Siemens

$0.00

(0.00%)

T

AT&T

$32.29

0.15 (0.47%)

RDS.A

Royal Dutch Shell

$63.29

0.84 (1.35%)

RHHBY

Roche

$0.00

(0.00%)

NVS

Novartis

$87.49

3.03 (3.59%)

BHP

BHP Group

$52.47

1.18 (2.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 29

    May

  • 29

    May

  • 31

    May

  • 03

    Jun

  • 03

    Jun

  • 03

    Jun

  • 05

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 11

    Jun

  • 12

    Jun

  • 20

    Jun

  • 23

    Jun

  • 16

    Jul

  • 24

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 02

    Sep

  • 04

    Nov

GM

General Motors

$35.13

0.01 (0.03%)

, TSLA

Tesla

$190.80

-4.7 (-2.40%)

13:19
05/25/19
05/25
13:19
05/25/19
13:19
Periodicals
Tesla stock in trouble, Barron's says »

Tesla (TSLA) stock is the…

GM

General Motors

$35.13

0.01 (0.03%)

TSLA

Tesla

$190.80

-4.7 (-2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

  • 05

    Jun

  • 11

    Jun

  • 01

    Aug

RNLSY

Renault

$0.00

(0.00%)

13:14
05/25/19
05/25
13:14
05/25/19
13:14
Periodicals
Renault stock may rally, Barron's says »

Shares of French auto…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMC

FMC Corporation

$70.88

-0.47 (-0.66%)

, DWDP

DowDuPont

$31.10

0.16 (0.52%)

13:11
05/25/19
05/25
13:11
05/25/19
13:11
Periodicals
DowDuPont spinoff a new agriculture stock, FMC safer bet, Barron's says »

The crop-protection and…

FMC

FMC Corporation

$70.88

-0.47 (-0.66%)

DWDP

DowDuPont

$31.10

0.16 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 25

    Jun

MGM

MGM Resorts

$25.55

0.19 (0.75%)

13:03
05/25/19
05/25
13:03
05/25/19
13:03
Periodicals
MGM Resorts looks like an attractive gambling play, Barron's says »

MGM Resorts (MGM) stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

PYPL

PayPal

$109.82

-0.09 (-0.08%)

, AXP

American Express

$119.52

1.07 (0.90%)

12:30
05/25/19
05/25
12:30
05/25/19
12:30
Periodicals
Big tech failed to dethrone credit cards, Barron's says »

Rather than being cut out…

PYPL

PayPal

$109.82

-0.09 (-0.08%)

AXP

American Express

$119.52

1.07 (0.90%)

MA

MasterCard

$251.40

1.57 (0.63%)

V

Visa

$162.72

1.2 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 03

    Jun

  • 05

    Jun

  • 06

    Jun

  • 11

    Jun

  • 25

    Jun

  • 13

    Nov

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

, GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

07:20
05/25/19
05/25
07:20
05/25/19
07:20
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

MSFT

Microsoft

$126.23

0.04 (0.03%)

AMBA

Ambarella

$38.28

1.07 (2.88%)

ON

ON Semiconductor

$17.68

-0.235 (-1.31%)

NKE

Nike

$82.12

-0.51 (-0.62%)

ADDYY

Adidas

$0.00

(0.00%)

UAA

Under Armour

$23.54

0.075 (0.32%)

UA

Under Armour

$20.91

0.08 (0.38%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

VMC

Vulcan Materials

$126.28

1.25 (1.00%)

FLR

Fluor

$29.04

0.18 (0.62%)

ACM

Aecom

$31.56

-0.03 (-0.09%)

X

U.S. Steel

$13.63

-0.08 (-0.58%)

AKS

AK Steel

$2.00

-0.155 (-7.21%)

NUE

Nucor

$51.12

-0.27 (-0.53%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$12.85

0.11 (0.86%)

F

Ford

$9.83

-0.02 (-0.20%)

GM

General Motors

$35.13

0.01 (0.03%)

HMC

Honda

$25.45

0.175 (0.69%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$118.54

1.16 (0.99%)

VWAGY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 03

    Jun

  • 03

    Jun

  • 04

    Jun

  • 04

    Jun

  • 05

    Jun

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Jun

  • 19

    Jun

  • 19

    Jun

  • 23

    Jun

  • 09

    Jul

  • 24

    Jul

  • 31

    Jul

  • 01

    Aug

  • 06

    Aug

  • 23

    Oct

  • 27

    Oct

UBER

Uber

$41.40

0.94 (2.32%)

17:49
05/24/19
05/24
17:49
05/24/19
17:49
Hot Stocks
Uber board director Ryan Graves intends to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

APTO

Aptose Biosciences

$2.01

0.03 (1.52%)

17:46
05/24/19
05/24
17:46
05/24/19
17:46
Syndicate
Aptose Biosciences files for $40M at-the-market common stock offering »

Piper Jaffray and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

TRNX

Taronis Technologies

$0.48

0.004 (0.84%)

17:26
05/24/19
05/24
17:26
05/24/19
17:26
Syndicate
Breaking Syndicate news story on Taronis Technologies »

Taronis Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:25
05/24/19
05/24
17:25
05/24/19
17:25
Hot Stocks
U.S. Energy discloses Nasdaq notice regarding delayed 10-Q filing »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

17:22
05/24/19
05/24
17:22
05/24/19
17:22
Periodicals
Apple sued over allegedly selling users' iTunes data, Bloomberg says »

Apple is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SPCB

SuperCom

$1.17

-0.005 (-0.43%)

17:21
05/24/19
05/24
17:21
05/24/19
17:21
Hot Stocks
SuperCom discloses Nasdaq notice regarding delayed 20-F filing »

SuperCom received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:20
05/24/19
05/24
17:20
05/24/19
17:20
Hot Stocks
U.S. Energy receives noncompliance notice from Nasdaq »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:18
05/24/19
05/24
17:18
05/24/19
17:18
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:17
05/24/19
05/24
17:17
05/24/19
17:17
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$87.49

3.03 (3.59%)

, QGEN

Qiagen

$38.22

-0.255 (-0.66%)

16:57
05/24/19
05/24
16:57
05/24/19
16:57
Hot Stocks
Qiagen launches diagnostic for PIK3CA biomarkers in breast cancer »

Qiagen (QGEN) announced…

NVS

Novartis

$87.49

3.03 (3.59%)

QGEN

Qiagen

$38.22

-0.255 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 20

    Jun

  • 06

    Aug

AVH

Avianca

$3.96

0.91 (29.84%)

16:56
05/24/19
05/24
16:56
05/24/19
16:56
Periodicals
ANAC suspends flights, operations of Avianca Brasil, Reuters reports »

Brazil's ANAC said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

16:53
05/24/19
05/24
16:53
05/24/19
16:53
Periodicals
Apple acquires startup Tueo Health, CNBC reports »

Apple has bought Tueo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SHSP

SharpSpring

$16.37

-0.24 (-1.44%)

16:52
05/24/19
05/24
16:52
05/24/19
16:52
Syndicate
Breaking Syndicate news story on SharpSpring »

SharpSpring files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

CREG

China Recycling Energy

$0.48

0.005 (1.05%)

16:41
05/24/19
05/24
16:41
05/24/19
16:41
Syndicate
Breaking Syndicate news story on China Recycling Energy »

China Recycling Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.